AUTL News & Events

Reports Q1 revenue $26.22M, consensus $26.13M. "In the first quarter, Autolus continued to expand market share for AUCATZYL in the US based on strong physician experience in adult ALL, and supported by reliable, high-quality product delivery. Our UK launch, which began in January, is off to a strong start, and we are expanding our reach in this market as well. We are pleased to report a turn to positive gross margin in the first quarter, and we expect continued improvement as we grow sales and manage costs," said Christian Itin, CEO of Autolus.

The company said, "Autolus reiterates its full year 2026 outlook for AUCATZYL net product revenue of between $120 million to $135 million, up from $74 million in 2025, as well as continued positive gross margin in 2026. Based on current operating plans, including anticipated AUCATZYL net revenues, Autolus expects that its current and projected cash, cash equivalents and marketable securities will be sufficient to fund the Company's operations into Q4 2027."

Autolus Therapeutics announced a strategic initiative and plan to improve operational efficiency and reduce operating expenses. As part of this initiative, the company is implementing a reduction in force affecting approximately 13% of its workforce. "With a strong first year of launch in 2025 and good momentum into this year, we are now focused on optimizing our operating model and driving cost efficiency," said Christian Itin, Autolus CEO. "These actions will enhance our margins, support scalable growth, and position Autolus for long-term value creation." The actions are expected to reduce operating expenses by approximately $15M on an annualized basis beginning in 2027. Autolus reiterates full year 2026 Aucatzyl net product revenue of $120M-$135M, as well as an anticipated shift to positive gross margin in 2026.